Cargando…
Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis
Targeting programmed cell death protein ligand 1 (PD-L1) remains one of the most essential immunotherapies in cancer(1,2). PD-L1 has been detected in the nucleus in multiple malignancies, playing an oncogenic role independent of immune checkpoint regulation(3–5). Howbeit, the regulatory function of...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Nature Singapore
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050073/ https://www.ncbi.nlm.nih.gov/pubmed/36977660 http://dx.doi.org/10.1038/s41421-023-00521-7 |